Phase II clinical trial of low-dose interleukin-2, interferon-alpha, and low-dose tegafur uracil therapy for advanced renal cell cancer.
Tomoyuki Kato(Aichi Cancer Center), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Tetsuo Fujita(National Hospital Organization Takamatsu Medical Center), Seiichi Saito(Hokkaido University), Takeshi Kishida(National Institutes of Health), Takehiro Sejima(Tottori University), Yoshinori Ohshiro(University of the Ryukyus), Masatsugu Iwamura(Kitasato University), Nozomu Kawata(Nihon University), Tomoyuki Imai(Niigata City General Hospital), Tatsuo Tochigi(Miyagi Prefectural Hospital Organization), Yoshihiko Tomita(Niigata University Medical and Dental Hospital)
Cited by 0
Related Papers
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253
Large-eddy simulation of flow around an isolated building: A step-by-step analysis of influencing factors on turbulent statistics
|Building and Environment|2021|139
Feasibility and Efficacy of Combination Therapy With Preoperative Full-Dose Gemcitabine, Concurrent Three-Dimensional Conformal Radiation, Surgery, and Postoperative Liver Perfusion Chemotherapy for T3-Pancreatic Cancer
|Annals of Surgery|2009|121
Plasma Membrane-associated Sialidase Is Up-regulated in Renal Cell Carcinoma and Promotes Interleukin-6-induced Apoptosis Suppression and Cell Motility
|Journal of Biological Chemistry|2006|116